Cynosure to Announce Second-Quarter 2008 Financial Results on July 29

Tuesday, July 15, 2008 General News J E 4
WESTFORD, Mass., July 15 Cynosure, Inc.(Nasdaq: CYNO), a leading developer and manufacturer of a broad array oflight-based aesthetic treatment systems, today announced that the company willhost its second-quarter 2008 conference call on Tuesday, July 29, 2008 at 9:00a.m. ET.

On the call, President and Chief Executive Officer Michael Davin andExecutive Vice President and Chief Financial Officer Timothy Baker willdiscuss Cynosure's second-quarter financial results, as well as the company'sbusiness outlook and growth strategy.

Those who wish to listen to the conference call webcast should visit the"Investor Relations" section of the company's website at live call also can be accessed by dialing (877) 407-5790 or(201) 689-8328. If you are unable to listen to the live call, the webcastwill be archived on the company's website.

About Cynosure, Inc.

Cynosure, Inc. develops and markets aesthetic treatment systems that areused by physicians and other practitioners to perform non-invasive andminimally invasive procedures to remove hair, treat vascular lesions,rejuvenate skin through the treatment of shallow vascular and pigmentedlesions, laser lipolysis and temporarily reduce the appearance of cellulite.Cynosure's products include a broad range of laser and other light-basedenergy sources, including Alexandrite, pulsed dye, Nd:YAG and diode lasers, aswell as intense pulsed light. Cynosure was founded in 1991.

For corporate or product information, contact Cynosure at 800-886-2966, orvisit Scott Solomon Vice President Sharon Merrill Associates, Inc. 617-542-5300

SOURCE Cynosure, Inc.


You May Also Like

View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
Journal of Clinical Oncology Publishes Study of Ce...
Alfacell Announces ONCONASE(R) Distribution and Ma...